M B Bally
Overview
Explore the profile of M B Bally including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
93
Citations
1914
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Verreault M, Wehbe M, Strutt D, Masin D, Anantha M, Walker D, et al.
J Control Release
. 2015 Nov;
220(Pt A):348-357.
PMID: 26528901
Our laboratory reported that Irinophore C™ (IrC™; a lipid-based nanoparticulate formulation of irinotecan) is effective against an orthotopic model of glioblastoma (GBM) and that treatment with IrC™ was associated with...
2.
Hope M, Bally M, Webb G, Cullis P
Biochim Biophys Acta
. 2012 Sep;
812(1):55-65.
PMID: 23008845
A technique for the rapid production of large unilamellar vesicles by repeated extrusion under moderate pressures (≤ 500 lb/in²) of multilamellar vesicles through polycarbonate filters (100 nm pore size) is...
3.
Verreault M, Strutt D, Masin D, Anantha M, Waterhouse D, Yapp D, et al.
J Control Release
. 2011 Oct;
158(1):34-43.
PMID: 22001870
Given compelling evidences supporting the therapeutic potential of irinotecan (IRN) for patients with glioblastoma (GBM), the present study evaluated the activity of Irinophore C™ (IrC™), a lipid-based nanopharmaceutical formulation of...
4.
Verreault M, Strutt D, Masin D, Fink D, Gill R, Bally M
Anticancer Res
. 2011 Jul;
31(6):2161-71.
PMID: 21737636
Unlabelled: Glioblastoma (GBM) cell lines expressing red fluorescent proteins were evaluated as a tool for non-invasive imaging of orthotopic tumors. Materials And Methods: mKate2- and mCherry-transduced U251MG GBM lines were...
5.
Wasan E, Reimer D, Harvie P, Kong S, Wong F, Bally M
Methods Mol Med
. 2011 Feb;
25:255-304.
PMID: 21318851
The overall goal of gene therapy is to cure or stabilize a disease process that results from the production of a mutant protein (for example, the chloride channel protein important...
6.
Ansell S, Harasym T, Tardi P, Buchkowsky S, Bally M, Cullis P
Methods Mol Med
. 2011 Feb;
25:51-68.
PMID: 21318840
Liposomes are useful drug delivery vehicles since they may protect encapsulated drugs from enzymatic degradation and rapid clearance in vivo, or alter biodistribution, potentially leading to reduced toxicities (1,2). A...
7.
Kalra J, Sutherland B, Stratford A, Dragowska W, Gelmon K, Dedhar S, et al.
Oncogene
. 2010 Sep;
29(48):6343-56.
PMID: 20838384
In a previous study it was found that the therapeutic effects of QLT0267, a small molecule inhibitor of integrin-linked kinase (ILK), were influenced by Her2/neu expression. To understand how inhibition...
8.
Qadir M, Kwok B, Dragowska W, To K, Le D, Bally M, et al.
Breast Cancer Res Treat
. 2008 Jan;
112(3):389-403.
PMID: 18172760
Macroautophagy (autophagy), a process for lysosomal degradation of organelles and long-lived proteins, has been linked to various pathologies including cancer and to the cellular response to anticancer therapies. In the...
9.
Waterhouse D, Gelmon K, Klasa R, Chi K, Huntsman D, Ramsay E, et al.
Curr Cancer Drug Targets
. 2006 Oct;
6(6):455-89.
PMID: 17017873
Combination chemotherapy has been at the forefront of cancer treatment for over 40 years. However, the rationale for selecting drug combinations and the process used to demonstrate clinical effectiveness has...
10.
Wong F, Macadam S, Kim A, Oja C, Ramsay E, Bally M
J Drug Target
. 2003 Apr;
10(8):615-23.
PMID: 12683666
Antisense oligodeoxynucleotides (ASOs) prevent expression of proteins by binding to specific regions of mRNA. This report investigates a potential lipid-based delivery system for ASO. A hydrophobic complex was recovered following...